Upcoming event
Masterclass on Partial nephrectomy
Back

Tags

Article of the Month, ASCO GU22, ASCO21, AUA21, Cabozantinib, Carcinoma, Chronic kidney disease, Cryosurgery, EAU, EAU21, EAU22, EMUC21, EMUC22, ERUS22, ESMO21, Frail patient​, Glomerular filtration rate, Guidelines, IMDC risk model, Kidney cancer, Laparoscopy, Lymph node metastases, Lymph nodes, Metastasectomy, Mortality, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, Overall survival, Partial nephrectomy, Prognostication, Radical nephrectomy, Radical surgery, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, Robotic, Robotic prostatectomy, Robotic surgery, Survival outcome, Suture, Targeted therapies, Treatment response, Urological surgery, UROonco24, UROwebinar, Webinar
Show all

Clinical applications of microbiome in renal cell carcinoma

European Urology Focus, January 2025

View

Abdominal noncontrast computed tomography scanning to screen for kidney cancer and other abdominal pathology within community-based computed tomography screening for lung cancer: Results of the Yorkshire kidney screening trial

European Urology, September 2024

View

[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial

The LANCET Oncology, October 2024

View

Effect of sex on the oncological outcomes in response to immunotherapy and antibody-drug conjugates in patients with urothelial and kidney cancer: A systematic review and a network meta-analysis

European Urology Oncology, April 2024

View

Preparing for the worst: Management and predictive factors of open conversion during minimally invasive renal tumor surgery (UroCCR-135 study)

European Urology Open Science, May 2024

View

Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial

The LANCET oncology, March 2024

View

Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk international metastatic renal cell carcinoma database consortium criteria treated by immune-oncology combinations: Differential effectiveness by risk group?

European Urology Oncology, February 2024

View

Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)

The Lancet Oncology, January 2024

View

Nephron Sparing Treatment (NEST) for small renal masses: A feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot-assisted partial nephrectomy

View

Development of a novel score (RENSAFE) to determine probability of acute kidney injury and renal functional decline post surgery: A multicenter analysis

View

Preoperative renal parenchyma volume as a predictor of kidney function following nephrectomy of complex renal masses

View

Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: A systematic literature review

View
Next